Condition: Psoriatic Arthritis · Secukinumab · Ultrasonography · Sponsor: Nanjing Medical University
Psoriatic arthritis (PsA) is a complex inflammatory disease with heterogeneous clinical features, which complicates psoriasis in 30% of patients. PsA involves multiple tissues and clinical domains including skins and nails as well as arthritis, spondylitis, enthesitis, and dactylitis. Power Doppler (PD) ultrasonography (PDUS) is a sensitive non-invasive imaging technology used to assess disease activity and treatment response in PsA. This is a prospective, observational, open-label study to investigate disease activity, therapeutic response and bone destruction based on ultrasonography findings in patients with PsA.
This description comes directly from the study's public registry record.
Rui Rui LIU, MD · +86 15951871668 · liurui_nanjing@163.com
Qian ZHANG, MD · +86 17702501489 · zhq19921012@163.com
Always discuss trial participation with your own doctor first.
| Department of Rheumatology and Immunology, Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
| Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06730334